NONOF - Novo Nordisk A/S

Other OTC - Other OTC Delayed price. Currency in USD
50.30
0.00 (0.00%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous close50.30
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume1,716
Avg. volume30,912
Market cap129.49B
Beta0.72
PE ratio (TTM)20.74
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield1.12 (2.23%)
Ex-dividend date2017-03-24
1y target estN/A
Trade prices are not sourced from all markets
  • Market Realistyesterday

    Novo Nordisk Stock: Performance in 3Q17

    Novo Nordisk stock has risen ~12.3% in 3Q17. It has risen ~41.3% year-to-date as of October 20, 2017.

  • Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling
    Zacksyesterday

    Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

    Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

  • Reuters - UK Focus3 days ago

    Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

    WASHINGTON/COPENHAGEN, Oct (Shenzhen: 000069.SZ - news) 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares (Berlin: DI6.BE - news) in Novo Nordisk (LSE: 0QIU.L - news) rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.

  • Reuters - UK Focus3 days ago

    U.S. FDA panel backs approval of Novo Nordisk diabetes drug

    WASHINGTON, Oct (Shenzhen: 000069.SZ - news) 18 (Reuters) - Novo Nordisk A/S (LSE: 0QIU.L - news) 's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly (Hanover: LLY.HA - news) & Co's once-weekly Trulicity, which in turn has been taking share from Novo Nordisk's once-daily Victoza.

  • Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
    Zacks3 days ago

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

  • Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
    Zacks11 days ago

    Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

  • Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal
    Zacks15 days ago

    Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

    The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

  • Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
    Zacks19 days ago

    Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

    Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

  • Reuters - UK Focus9 months ago

    European shares fall weighed down by poor earnings; Reckitt up

    European shares slipped on Thursday, weighed down by disappointing earning updates from Danish drugmaker Novo Nordisk and German lender Deutsche Bank, although Reckitt Benckiser was boosted by news of ...

  • Falling US prices hurt Danish Novo Nordisk profit
    AFP9 months ago

    Falling US prices hurt Danish Novo Nordisk profit

    Novo Nordisk profits were hurt by falling prices in the United States, a huge market for the Danish company

  • Reuters - UK Focus9 months ago

    European shares edge lower on disappointing company updates

    European shares fell on Thursday after disappointing company updates, with Denmark's Novo Nordisk leading the market down and Finnish retailer Kesko weakening on lower-than-expected sales. The pan-European ...

  • Reuters - UK Focus9 months ago

    Danish drugmaker Novo Nordisk bets $145 mln on post-Brexit UK science

    Novo Nordisk (LSE: 0QIU.L - news) , the world's top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research centre in Britain, undeterred by Brexit. The Danish company said on Monday it would invest the money over 10 years in the centre based at the University of Oxford, which will employ 100 scientists hunting for new ways to treat type 2 diabetes.

  • Reuters - UK Focus10 months ago

    BUZZ-European Pharma: UBS shuffles recommendations

    ** UBS analysts say investors in healthcare stocks should seek exposure to oncology and new expensive drugs which displace older expensive drugs; avoid therapy areas at risk of becoming crowded and new ...

  • Reuters - UK Focus11 months ago

    Pharma, biotech shares soar as Trump win calms pricing talk

    NEW YORK/LONDON, Nov 9 (Reuters) - Pharmaceutical and biotechnology shares soared on Wednesday as Republican Donald Trump's U.S. presidential election calmed investor fears of tough action on drug pricing that has pressured the sector for more than a year. Hospital shares tumbled as a Republican sweep of Congress raised prospects for a rollback of the Affordable Care Act (ACA), which expanded the number of patients in government health plans. Fears of a win by Hillary Clinton and Democrats gaining power in Congress had clouded the outlook for biotech and pharma shares and contributed to general underperformance for the U.S. healthcare sector this year.

  • Novo Nordisk cuts profit forecast amid US challenges
    AFPlast year

    Novo Nordisk cuts profit forecast amid US challenges

    For the second time this year, Novo Nordisk halved a long-term profit target that had been in place for 20 year

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes